Can an immune-boosting drug make chemotherapy more effective against sarcoma?

NCT ID NCT04874311

Ongoing Disease control Sponsor: Institut Bergonié Source: ClinicalTrials.gov ↗

First seen Jul 24, 2026 · Last updated Jul 24, 2026

Summary

This phase 2 trial is testing whether adding bintrafusp alfa, an experimental immunotherapy, to standard doxorubicin chemotherapy can help control advanced soft-tissue sarcoma. The study includes people with metastatic or unresectable tumors and looks at how well the combination slows cancer growth over six months. Researchers are also comparing effects in tumors with different immune profiles.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bintrafusp alfa combined with doxorubicin chemotherapy
What this could lead to: If successful, this combination could offer a new treatment option for people with advanced soft-tissue sarcoma that is hard to treat.
What could go wrong: This is an early-phase trial with a small number of participants. The combination may cause significant side effects, and it is not yet known if it works better than standard care alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOFT TISSUE SARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Neoplasm Metastasis sarcoma soft tissue sarcoma Tertiary Lymphoid Structures

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOFT TISSUE SARCOMA METASTATIC SOFT-TISSUE SARCOMA

Contacts and locations

Show contact details

Locations

CHU Poitiers

Poitiers, 86000, France
Centre Georges François Leclerc

Dijon, 21079, France
Centre Léon Bérard

Lyon, 69000, France
Institut Bergonie

Bordeaux, 33000, France
Institut Curie

Paris, 75000, France
Institut Paoli Calmette

Marseille, 13000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.